Osimertinib

Osimertinib Reactions 1680, p270 - 2 Dec 2017 Acquired resistance to osimertinib: case report In a study of 86 patients, a patient [age and sex not stated] was described, who acquired resistance to osimertinib during treatment of a non-small-cell lung carcinoma [route, dosage and duration of treatment to reaction onset not stated]. The patient, who had T790M-positive non-small-cell lung carcinoma, started receiving treatment with osimertinib. Subsequently, a serial plasma genotyping confirmed the acquired KRAS Q61K mutation on osimertinib therapy [outcome not stated]. Author comment: "The remaining 11 [patients] had loss of T790M, of whom 5 had evidence of a competing resistance mechanism: 2 with histologic transformation to SCLC, one with BRAF V600E, one with an FGFR3-TACC fusion, and one with KRAS Q61K." "For the final case, we confirmed the acquired KRAS Q61K on therapy using serial plasma genotyping." Oxnard GR, et al. Overgrowth of competing resistance mechanisms, such as an acquired KRAS mutation, underlies a poor prognosis subtype of acquired resistance to osimertinib in T790M-positive NSCLC. Cancer Research 77 (Suppl. 1): abstr. 4112, No. 13, Jul 2017. Available from: URL: http:// doi.org/10.1158/1538-7445.AM2017-4112 [abstract] - USA 803284799 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Reactions Weekly Springer Journals

Osimertinib

Reactions Weekly , Volume 1680 (1) – Dec 2, 2017
Free
1 page

Loading next page...
1 Page
 
/lp/springer_journal/osimertinib-g0Z0KX8GuC
Publisher
Springer Journals
Copyright
Copyright © 2017 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
ISSN
0114-9954
eISSN
1179-2051
D.O.I.
10.1007/s40278-017-39201-7
Publisher site
See Article on Publisher Site

Abstract

Reactions 1680, p270 - 2 Dec 2017 Acquired resistance to osimertinib: case report In a study of 86 patients, a patient [age and sex not stated] was described, who acquired resistance to osimertinib during treatment of a non-small-cell lung carcinoma [route, dosage and duration of treatment to reaction onset not stated]. The patient, who had T790M-positive non-small-cell lung carcinoma, started receiving treatment with osimertinib. Subsequently, a serial plasma genotyping confirmed the acquired KRAS Q61K mutation on osimertinib therapy [outcome not stated]. Author comment: "The remaining 11 [patients] had loss of T790M, of whom 5 had evidence of a competing resistance mechanism: 2 with histologic transformation to SCLC, one with BRAF V600E, one with an FGFR3-TACC fusion, and one with KRAS Q61K." "For the final case, we confirmed the acquired KRAS Q61K on therapy using serial plasma genotyping." Oxnard GR, et al. Overgrowth of competing resistance mechanisms, such as an acquired KRAS mutation, underlies a poor prognosis subtype of acquired resistance to osimertinib in T790M-positive NSCLC. Cancer Research 77 (Suppl. 1): abstr. 4112, No. 13, Jul 2017. Available from: URL: http:// doi.org/10.1158/1538-7445.AM2017-4112 [abstract] - USA 803284799 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680

Journal

Reactions WeeklySpringer Journals

Published: Dec 2, 2017

There are no references for this article.

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off